BlackRock Institutional Trust’s Ionis Pharmaceuticals IONS Stock Holding History

BlackRock Institutional Trust’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$150M	Buy	3,135,136 +151,644	+5%	+$6M	0.02%	702
2016 Q3	$109M	Sell	2,983,492 -72,503	-2%	-$2.27M	0.02%	830
2016 Q2	$71.2M	Buy	3,055,995 +32,301	+1%	+$1.04M	0.01%	1035
2016 Q1	$122M	Buy	3,023,694 +8,712	+0.3%	+$354K	0.02%	734
2015 Q4	$187M	Sell	3,014,982 -32,664	-1%	-$1.76M	0.03%	569
2015 Q3	$123M	Buy	3,047,646 +32,199	+1%	+$1.67M	0.02%	732
2015 Q2	$174M	Sell	3,015,447 -145,450	-5%	-$9.25M	0.03%	626
2015 Q1	$201M	Buy	3,160,897 +177,076	+6%	+$12M	0.03%	573
2014 Q4	$184M	Sell	2,983,821 -104,599	-3%	-$5.16M	0.03%	578
2014 Q3	$120M	Sell	3,088,420 -121,051	-4%	-$4.29M	0.02%	745
2014 Q2	$111M	Buy	3,209,471 +77,929	+2%	+$2.45M	0.02%	829
2014 Q1	$135M	Buy	3,131,542 +39,641	+1%	+$1.92M	0.02%	719
2013 Q4	$123M	Buy	3,091,901 +28,364	+0.9%	+$1.01M	0.02%	742
2013 Q3	$115M	Sell	3,063,537 -190,241	-6%	-$5.68M	0.02%	708
2013 Q2	$87.4M	Buy	+3,253,778	New	+$69.2M	0.02%	807

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BlackRock Institutional Trust's IONS Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Ionis Pharmaceuticals (IONS) stake by 5.1% in Q4 2016, buying an estimated $6M and bringing the position to 3,135,136 shares worth $150M. The position accounts for 0.02% of the portfolio, ranked #702.

BlackRock Institutional Trust first reported a position in IONS in Q2 2013 and has held it in 15 quarters since. The position peaked at $201M in Q1 2015. 309 funds tracked by Wall St. Rank hold IONS as of Q4 2016.

BlackRock Institutional Trust held 3,135,136 shares of Ionis Pharmaceuticals worth $150M as of Q4 2016.
BlackRock Institutional Trust bought 151,644 Ionis Pharmaceuticals shares in Q4 2016, an estimated $6M.
Ionis Pharmaceuticals made up 0.02% of BlackRock Institutional Trust's portfolio in Q4 2016, its #702 holding.
BlackRock Institutional Trust first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
BlackRock Institutional Trust's Ionis Pharmaceuticals position peaked at $201M in Q1 2015.
309 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.